TY - JOUR T1 - Systemic corticosteroids doses in COPD exacerbations treated with non-invasive ventilation JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA2177 VL - 48 IS - suppl 60 SP - PA2177 AU - Nestor Rodriguez Melean AU - Daniel Lopez Padilla AU - Perla Valenzuela Reyes AU - Maria Emilia Banderas Montalvo AU - Luis Lopez Yepes AU - Ana Hernandez Both AU - Javier Sayas Catalan Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA2177.abstract N2 - Objective: Determine the effect of the first corticosteroid dose on success of Non-invasive ventilation (NIV) in COPD exacerbationsMethods: Observational, retrospective study. January-2013/June-2015. Patients with ≥ 1,5 mg/kg/day of methylprednisolone in the first 24 hours, were compared to those treated with lower doses. Baseline characteristics, pulmonary function, obstructive sleep apnea, and arterial blood gases (ABG) at admission/discharge were retrieved. NIV failure (No pH correction in 72 hours, need of invasive ventilation, or death). Adverse effects were collected. Quantitative variables with normal distribution (t-student), with non normal distribution (Kruskal-Wallis). Qualitative variables (Chi-square - Fisher exact correction)Results: 85 COPD patients with exacerbation, in need of NIV. 70 men (82%), mean age 68.6 ± 11.4 years. Mean dose of methylprednisolone 1.67 ± 0.82 mg/kg/first day, 43 patients (51%) were treated with < 1,5 mg/kg/day. There was a significant increase of pH (7.26 vs. 7.41; p=0.001) and decrease of pCO2 (86.8 vs. 61.5; p=0.001) between admission and at discharge. NIV failure was observed in 18 patients (21%) Conclusions: No differences on NIV success according to methylprednisolone doses. Doses ³ 1,5 mg/kg/day were used in patients with worst ABG at admission, with a slower pH correction, but with a reduced number of days of admission. No differences in adverse effects were observed. ER -